# Imaging of Coronary Plaques in Participants Treated With Evolocumab

Study · id `cardio:ct-nct03570697` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03570697](<https://clinicaltrials.gov/study/NCT03570697>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03570697

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 164 participants.

## Technical summary

Registry record NCT03570697. Randomized; triple masking; primary purpose treatment. Start 2018-11-19 (actual); primary completion 2020-12-18 (actual). Results posted on 2021-11-24.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 164 participants (enrolled count; ClinicalTrials.gov record NCT03570697, source copy `cardio:ctgov-nct03570697-2022-05-03`, retrieved 2026-10-26)
- Started: 2018-11-19 (actual) (ClinicalTrials.gov record NCT03570697, source copy `cardio:ctgov-nct03570697-2022-05-03`, retrieved 2026-10-26)
- Primary completion: 2020-12-18 (actual) (ClinicalTrials.gov record NCT03570697, source copy `cardio:ctgov-nct03570697-2022-05-03`, retrieved 2026-10-26)
- Completion: 2021-01-21 (actual) (ClinicalTrials.gov record NCT03570697, source copy `cardio:ctgov-nct03570697-2022-05-03`, retrieved 2026-10-26)
- Results first posted: 2021-11-24 (ClinicalTrials.gov record NCT03570697, source copy `cardio:ctgov-nct03570697-2022-05-03`, retrieved 2026-10-26)
- Countries: United States; Australia; Czechia; Germany; Hungary; Italy; Netherlands (ClinicalTrials.gov record NCT03570697, source copy `cardio:ctgov-nct03570697-2022-05-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03570697-2022-05-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Imaging of Coronary Plaques in Participants Treated With Evolocumab
- Condition: Coronary Artery Disease (CAD)
- Intervention (Drug): Evolocumab
- Intervention (Drug): Placebo
- Intervention (Drug): Statin therapy
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction (`cardio:pubmed-35431172`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS (`cardio:pubmed-40020597`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis (`cardio:pubmed-40424182`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2bae01a4a69934e433a77367fd30d8471da99394f182a1a81cd5b39d04fc2f12
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
